Repatha (evolocumab)

pCPA File Number: 21004
Negotiation Status:
Concluded without agreement
Indication(s):
Primary hyperlipidemia and mixed dyslipidemia
Sponsor/Manufacturer:
Amgen Canada Inc.
CDA-AMC Project Number:
SR0515-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: